Lagis Enterprise Co., Ltd. AI Stock Analysis
Lagis Enterprise Co., Ltd. (6730) AI Stock Analysis
Lagis Enterprise Co., Ltd.
(TPEx:6730)
The score is anchored by solid fundamentals: consistent revenue growth, durable high-40s gross margins, a conservatively capitalized balance sheet with sharply reduced debt, and a strong rebound in operating and free cash flow. Valuation adds support, with a low 8.1x P/E, a 4.66% dividend yield and low volatility (beta 0.35). The main drag is technical: the stock trades below all key moving averages with a slightly negative MACD and neutral RSI, signaling limited near-term momentum. Investors should also monitor whether the recent capital investment cycle translates into margin expansion, as return on equity has slipped to 9.1% and free cash flow conversion remains thin.
Lagis Enterprise Co., Ltd. (6730) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.13B
- Dividend Yield
- 4.64%
- Average Volume (3M)
- 10.19K
- Price to Earnings (P/E)
- 8.1
- Beta (1Y)
- 0.35
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- TW
- Employees
- 238
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Lagis Enterprise Co., Ltd. Business Overview & Revenue Model
Company Description
Lagis Enterprise Co., Ltd. is a medical technology company focused on the development and global distribution of specialized devices for laparoscopic and endoscopic surgical procedures. Their comprehensive product portfolio includes trocars, single-p...
Lagis Enterprise Co., Ltd. Financial Statement Overview
Summary
Lagis is a financially sound, steadily growing medical device supplier. Revenue rose ~7% to NT$487.6M with durable gross margins near 48% and a 14.2% net margin. The balance sheet is conservative, with equity funding roughly two-thirds of assets and debt cut nearly in half to NT$267.8M (0.35x debt-to-equity). Cash flow improved sharply, with operating cash flow up 78% to NT$131.7M and free cash flow turning positive at NT$39.6M after two years of outflows. Offsetting these strengths, profit growth (+1.5%) trailed revenue growth, margins have slipped from 2022 highs, return on equity fell to 9.1% on the larger capital base, and heavy capex still absorbs most operating cash.
Income Statement
72PositiveBalance Sheet
70PositiveCash Flow
65Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 492.35M | 487.65M | 454.36M | 459.93M | 442.19M | 393.04M |
| Gross Profit | 229.19M | 236.20M | 221.42M | 218.89M | 222.88M | 178.28M |
| EBITDA | 139.09M | 130.66M | 116.97M | 112.36M | 120.58M | 92.31M |
| Net Income | 68.69M | 69.27M | 68.24M | 64.11M | 71.04M | 48.94M |
Balance Sheet | ||||||
| Total Assets | 1.17B | 1.14B | 1.09B | 845.39M | 658.75M | 594.07M |
| Cash, Cash Equivalents and Short-Term Investments | 113.93M | 95.29M | 69.20M | 89.86M | 128.52M | 150.74M |
| Total Debt | 262.54M | 267.76M | 394.37M | 177.66M | 9.03M | 10.13M |
| Total Liabilities | 427.49M | 377.35M | 506.34M | 304.62M | 124.49M | 98.89M |
| Stockholders Equity | 739.75M | 761.99M | 579.80M | 540.77M | 534.26M | 495.18M |
Cash Flow | ||||||
| Free Cash Flow | 80.06M | 39.64M | -202.05M | -148.51M | 14.34M | 66.72M |
| Operating Cash Flow | 126.50M | 131.68M | 74.06M | 77.49M | 84.27M | 96.24M |
| Investing Cash Flow | -47.84M | -91.37M | -275.80M | -226.00M | -69.75M | -29.52M |
| Financing Cash Flow | -10.56M | -14.23M | 181.03M | 109.89M | -36.77M | -30.71M |
Lagis Enterprise Co., Ltd. Peers Comparison
Overall Rating
- TW:673068Neutral
TW:410945Neutral
TW:419842Neutral
TW:371030Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6730 | 68Neutral | TWD 1.17B | 8.07 | ― | 4.64% | ― | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4109 | 45Neutral | TWD 1.21B | 255.00 | ― | 1.96% | 13.00% | 902.22% |
| TW:4198 | 42Neutral | TWD 1.10B | -27.20 | ― | ― | ― | ― |
| TW:3710 | 30Underperform | TWD 1.35B | -1.57 | ― | ― | -1.88% | -7106.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6730 | Lagis Enterprise Co., Ltd. | 31.00 | -9.83 | -24.08% | |
| TW:3710 | ACON Holding Inc. | 7.32 | -5.80 | -44.22% | |
| TW:4109 | Jia Jie Biomedical Co., Ltd. | 10.25 | -5.46 | -34.76% | |
| TW:4198 | S&S Healthcare Holding Ltd. | 48.00 | 10.35 | 27.49% | |
| TW:6543 | Perfect Medical Industry Co., Ltd. | 16.55 | -11.20 | -40.36% | |
| TW:6847 | PuriBlood Medical Co.,Ltd. | 70.40 | -2.46 | -3.38% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026